Citations

Clear

21 citation(s) found for "Chen, Jie".

Added Value of Shear Wave Elastography for Noninvasive Detection of Axillary Lymph Node Metastasis and IHC-Defined Surrogate Subtype Characterization in Breast Cancer
Chen, Jie, Rosen, David , Parvar, Tanin Adl , Fazzio, Robert T. , Larson, Nicholas B. , Fatemi, Mostafa , Alizad, Azra

Mayo Clinic

Cancers | November 4, 2026 | Volume: 18 | Issue: 21 | Pages: 3549

10.3390/cancers18213549 Get It

Background: Accurate preoperative characterization of axillary lymph nodes (ALNs) is important in breast cancer, but conventional ultrasound has variable diagnostic performance. We evaluated quantitative shear wave elastography (SWE) for distinguishing reactive from metastatic ALNs, and we explored associations between nodal SWE parameters, breast cancer subtypes, and histological grades. Methods: We prospectively enrolled women with suspicious breast lesions and ALNs identified by clinical ultrasound who were scheduled for biopsy. After exclusions, 141 patients (57 reactive and 84 metastatic ALNs) were included. ElasticNet-regularized logistic regression with nested cross-validation compared clinical ultrasound alone with ultrasound plus SWE. Among 70 patients with metastatic ALNs and immunohistochemical characterization, SWE parameters were compared across surrogate subtypes and histological grades using Kruskal–Wallis tests with Holm adjustments. Results: The combined ultrasound–SWE model achieved an area under the receiver operating characteristic curve of 0.911 (95% CI, 0.859–0.961) compared to 0.798 (95% CI, 0.723–0.873) for ultrasound alone. At the Youden-derived threshold, the combined model achieved 88.1% sensitivity, 82.5% specificity, and 85.8% accuracy. Among metastatic ALNs, SWE parameters, namely Vmean, Vsd, and Vmax, differed significantly across surrogate subtypes, with the most pronounced differences observed between Luminal A and Luminal B tumors, (p = 0.0250, p = 0.0069, and p = 0.0065). No statistically significant differences were detected with histological grades in the five SWE parameters. Conclusions: Quantitative SWE complemented conventional ultrasound for assessing axillary nodal metastasis, with higher cross-validated discrimination for the combined model. Exploratory analyses identified differences in several SWE stiffness metrics between Luminal A and Luminal B tumors; these subtype-associated biomechanical differences require validation in larger cohorts.
Targeting Androgen Receptor as a Novel Radiosensitizing Therapy to Improve Long-Term Survival and Anti-tumor Immunity in Glioblastoma via TGF-β/Smad3 Axis Reprogramming
Zhang, C., Kaushal, Jyoti , Zhao, Nan, Liu, K., Wang, F., Chen, Jie , Guan, Bingjie , Wang, Shuo, Hei, Tom, Wang, Tony, Lei, Yuguo, lin, c, Zhang, Chi , Zhang, Chi , Hei, Tom , Zhao, Nan, Khan, Rubayat Islam , Aizenberg, Michele R.

Mayo Clinic

No container title available | February 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8585892/v1 | PMID 41674836 Get It

Abstract Glioblastoma (GBM) remains the most aggressive primary adult brain cancer with limited therapeutic options. Our prior research demonstrated that androgen receptor antagonists (ARAs) enhance survival in GBM mouse models by preferentially suppressing glioma stem cells. This study investigates the potential of ARAs as radiosensitizers in combination with radiotherapy (RT). Combined effects of ARAs and RT were evaluated using an orthotopic GBM mouse model. RNA-Seq and TCGA analyses delineated AR-associated regulatory networks, while integrated cellular and molecular approaches utilizing human and mouse GBM cell lines, as well as in patient-derived primary high-grade glioma cultures, interrogated signaling and immune paradigms. ARA treatment induced G2/M cell cycle arrest, apoptosis, and downregulated DNA repair genes, with AR expression correlating with the DNA repair and TGF-β pathway. In both immortalized GBM cell lines and primary high-grade glioma cultured cells, ARAs in combination with RT showed only a modest enhancement of radiosensitivity. However, in an orthotopic GBM mouse model, ARA + RT demonstrated a strong synergy, achieving 100% long-term survival, compared to less than 50% with ARA alone and 0% with RT alone. Mechanistically, ARA modulated the TGF-β pathway, durably switching from Smad3 linker to c-terminal phosphorylation (pSmad3C) and inhibiting LIF/STAT3 axis. Distinct TGF-βs ligand expression patterns were observed in ARA-treated GBM cells. A protein–protein interaction noted between AR and Smad3, which was disrupted following ARA treatment, leading to elevated protein levels and nuclear localization of pSmad3C (S423/425), indicating normalization/activation of the TGF-β/pSmad3C-dependent anti-tumorigenic cascade. Comprehensive analyses in GBM cell lines and mouse model tissues demonstrated pathway reprogramming characterized by elevated TGF-β2 and increased pSmad3C. Tissue analysis revealed immune activation in the tumor microenvironment, while peripheral blood and spleen showed systemic immune responses following ARA + RT. Our study provides novel insights into how ARAs enhance RT efficacy through immunomodulation involving TGF-β/pSmad3C cascade, offering therapeutic implications in GBM.
Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases
Rajan, Sharika, Chung, Hye‐Jung, Wu, Zhichao , Dazelle, Karen , Abdullaev, Zied , Tyagi, Manoj, Ferrone, Christina K. , Raffeld, Mark , Lee, Ina, Chen, Jie , Cathcart, Sahara , Giannini, C., Nguyen, Aivi, Gökden, Murat , Perry, A., Fernandes, Igor Lima , Putnam, Angelica R. , Kurek, Kyle C., Green, Richard M, Lucas, Calixto-Hope, González-Gómez, Ignacio, Lopez, G., Ra, Prayson, Yeaney, Gabrielle , Dermawan, Josephine Kam Tai, Chkheidze, Rati , Appin, Christina , Uhlmann, Erik J. , Taliansky, A , Blessing, Melissa M. , Mohila, Carrie, Deisch, Jeremy , Andreiuolo, Felipe, Crawford, John R, Stemmer‐Rachamimov, Anat , Lakis, Nelli S., Re, Schmidt, Chacko, Geeta, Newbury, Robert, Neill, Stewart G. , Morales, Bryan , Fecher, Roger , Sloan, Emily A. , Solomon, David A, Nasrallah, MacLean, Quezado, Martha, Aldape, Kenneth, Solomon, David A. , Chen, Jie , Giannini, Caterina , Perry, Arie , Chkheidze, Rati , Deisch, Jeremy , Solomon, David A , Aldape, Kenneth , Jones, Karra A , López, Giselle Y. , Wu, Zhichao, Singh, Omkar, Gagan, Jeffrey , Nguyen, Aivi, Perry, Arie , Green, Richard M., Eberhart, Charles G. , Lucas, Calixto-Hope C. , Jones, Karra A. , Mohila, Carrie , Cotter, Jennifer A. , Andreiuolo, Felipe , Crawford, John R, Mount, Christopher , Lakis, Nelli S., Schmidt, Robert, Chacko, Geeta , Nasrallah, MacLean P. , Quezado, Martha , Fonseca, Adriana

Mayo Clinic

Neuro-Oncology | January 17, 2026 | Volume: 28 | Issue: 4 | Pages: 939-951

10.1093/neuonc/noag001 | PMID 41569358 Get It

Abstract Background Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1, or CREM). The methylation signature(s), gene expression characteristics, and clinical behavior of this important tumor type require further characterization. Methods We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. Results ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases), and SMARCA2::CREM (4 cases). We confirmed the prior description of 2 distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed a higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (P < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone or a larger group of CNS tumors. Conclusions This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.
Secondary Neurolymphomatosis after 11 Years of Remission of CNS Lymphoma: A Case Report (P7-11.005)
Riley, H D, Chen, Jie , Dyck, Peter James , Thaisetthawatkul, Pariwat , Riley, Haley

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211164 Get It

Free‐breathing hepatic 2D magnetic resonance elastography
Li, Jiahui , Chen, Jie , Glaser, Kevin J. , Yin, Ziying , Le, Yuan , Shah, Vijay H. , Obrzut, Marzanna, Yin, Ziying , Le, Yuan , Manduca, A , Ehman, Richard , Li, Jiahui , Obrzut, Marzanna , Dzyubak, Bogdan , Chen, Jun , Allen, Alina M. , Venkatesh, Sudhakar K. , Manduca, Armando , Ehman, Richard L. , Yin, Meng

Mayo Clinic

Magnetic Resonance in Medicine | March 11, 2025 | Volume: 93 | Issue: 6 | Pages: 2434-2443

10.1002/mrm.30483 | PMID 40033890 Get It

Abstract Purpose To evaluate the test–retest repeatability of a rapid, free‐breathing two‐dimensional (2D) MR elastography (MRE) technique and to assess the reliability of the liver‐stiffness measurements compared with conventional breath‐hold MREs. Methods Fifteen and 115 participants were enrolled in the technical repeatability and measurement equivalence assessment cohorts, respectively. All participants underwent rapid free‐breathing and conventional breath‐hold 2D MRE (twice in repeatability cohort) on 1.5T scanners. Both methods have four phase offsets over one harmonic motion cycle at 60 Hz; one and 10 cycles were collected and processed in breath‐hold and free‐breathing MREs, respectively. The liver stiffness measurements of free‐breathing (LS F ) and breath‐hold MRE (LS B ) were calculated from manually drawn regions of interest. The repeatability coefficients and Spearman correlation were used to assess technical repeatability and measurement agreement between LS F and LS B . Univariable and multivariable linear regressions were performed to identify potential influencing factors, including age, sex, body mass index, and fat fraction, in the measurement agreement between LS B and LS F . Results The repeatability coefficient of free‐breathing 2D MRE is comparable to breath‐hold MRE (LS F : 20.8%, LS B : 20.4%). LS F showed a strong agreement and significant correlation with LS B (LS F = 1.01 × LS B , ρ = 0.94, p < 0.001). The measurement agreement between LS F and LS B was only significantly affected by sex ( p = 0.047) after adjusting for confounding factors of age, body mass index, and fat fraction. Conclusions The nongated, free‐breathing, multislice 2D MRE technique can provide reliable liver stiffness measurements compared with conventional breath‐hold 2D MRE. It could provide a comfortable alternative method with reliable liver stiffness measurements for patients who have difficulty in suspending respiration.
Magnetic Resonance Elastography Combined With PI‐RADS v2.1 for the Identification of Clinically Significant Prostate Cancer
Chen, Jie , Chen, Yuntian , Deng, Liping , Tang, Hehan , Zhang, Zhen , Chen, Tingyu , Zeng, Hao , Yuan, Enyu , Yao, Jin , Song, Bin , Yao, Jin , Chen, Guoyong , Yuan, Yuan , Yin, Meng , Chen, Jun

Mayo Clinic

Journal of Magnetic Resonance Imaging | November 8, 2024 | Volume: 61 | Issue: 5 | Pages: 2248-2257

10.1002/jmri.29653 | PMID 39513399 Get It

BackgroundMultiparametric MRI may cause overdiagnosis of clinically significant prostate cancer (csPCa) with the Prostate Imaging Reporting and Data System version 2.1 (PI‐RADS v2.1).ObjectivesTo investigate the diagnostic performance of stiffness as a standalone and complementary marker to PI‐RADS v2.1 for diagnosing csPCa.Study TypeProspective.SubjectsOne hundred forty‐seven participants with pathologically confirmed prostate lesions (≥1 cm), including 71 with csPCa.Field Strength/SequenceT1‐weighted fast spin‐echo, T2‐weighted fast spin‐echo, single‐shot echo‐planar diffusion‐weighted imaging, fast 3D gradient‐echo T1‐weighted dynamic contrast‐enhanced imaging, and 3D single‐shot spin‐echo based echo‐planar MR elastography at 3.0 T.AssessmentThe PI‐RADS v2.1 score was assessed by three radiologists independently. Lesion shear stiffness (SS) values at 60 Hz and 90 Hz were measured. A modified PI‐RADS integrating stiffness with PI‐RADS v2.1 was developed. Diagnostic performance for csPCa was compared between stiffness, PI‐RADS v2.1 and the modified PI‐RADS.Statistical TestSpearman's correlation, Fleiss κ and intraclass correlation, Pearson correlation, one‐way analysis of variance, area under the receiver operating characteristic curve (AUC), and the Delong test. Significance level was P < 0.05.ResultsIn the peripheral zone, csPCa (N = 35) had significantly higher SS than non‐csPCa at 60 Hz (3.22 ± 0.66 kPa vs. 2.56 ± 0.56 kPa) and at 90 Hz (5.64 ± 1.30 kPa vs. 4.48 ± 0.84 kPa). PI‐RADS v2.1 showed 100% sensitivity, 58% specificity, and 0.79 AUC for detecting csPCa. SS achieved 97% sensitivity, 52% specificity, and 0.80 AUC at 60 Hz, while SS had 63% sensitivity, 87% specificity, and 0.78 AUC at 90 Hz. The modified PI‐RADS, combing SS at 60 Hz with PI‐RADS v2.1, resulted in a significantly increased AUC (0.86) compared to that of PI‐RADS v2.1, with a sensitivity of 97% and specificity of 75%.Data ConclusionStiffness can help identifying csPCa in the peripheral zone. Combining stiffness with the PI‐RADS v2.1 improved the diagnostic accuracy and specificity for csPCa.Evidence Level1Technical EfficacyStage 2
Obsidio Gel Occlusion for Persistent Air Leak - An Innovational Non-surgical Approach to Heal
Chen, Jie , Abdalla, A.A., Fanous, J., McNierney, Dakota , Sakata, Kenneth K. , Fanous, J.

Mayo Clinic

B104. CASE REPORTS IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4820-A4820

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4820 Get It

Multi-Organ Complexities in Telomere Biology Disorders: Liver Cirrhosis, Pulmonary Fibrosis, and Transplantation Challenges
Fanous, J., McNierney, Dakota , Chen, Jie , Peters, Steve G. , Omar, Ahmad Afiq Irshad, Patnaik, Mrinal M. , Barnhill, Michele , Porquera, Eva M. Carmona, Zamora-Martinez, A.C., Kennedy, Cassie C. , Omar, A., Ferrer, Alejandro

Mayo Clinic

C54. CASE REPORTS IN LUNG TRANSPLANT | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5945-A5945

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5945 Get It

Enrollment in High-Deductible Health Plans and Incident Diabetes Complications
Swarna, Kavya, Jiang, David H. , Houten, Holly K. Van , Davis, Esa M. , Swarna, Kavya S, McCoy, Rozalina G. , Chen, Jie, Herrin, Jeph

Mayo Clinic

JAMA Network Open | March 22, 2024 | Volume: 7 | Issue: 3 | Pages: e243394

10.1001/jamanetworkopen.2024.3394 | PMID 38517436 Get It

ImportancePreventing diabetes complications requires monitoring and control of hyperglycemia and cardiovascular risk factors. Switching to high-deductible health plans (HDHPs) has been shown to hinder aspects of diabetes care; however, the association of HDHP enrollment with microvascular and macrovascular diabetes complications is unknown.ObjectiveTo examine the association between an employer-required switch to an HDHP and incident complications of diabetes.Design, Setting, and ParticipantsThis retrospective cohort study used deidentified administrative claims data for US adults with diabetes enrolled in employer-sponsored health plans between January 1, 2010, and December 31, 2019. Data analysis was performed from May 26, 2022, to January 2, 2024.ExposuresAdults with a baseline year of non-HDHP enrollment who had to switch to an HDHP because their employer offered no non-HDHP alternative in that year were compared with adults who were continuously enrolled in a non-HDHP.Main Outcomes and MeasuresMixed-effects logistic regression models examined the association between switching to an HDHP and, individually, the odds of myocardial infarction, stroke, hospitalization for heart failure, lower-extremity complication, end-stage kidney disease, proliferative retinopathy, treatment for retinopathy, and blindness. Models were adjusted for demographics, comorbidities, and medications, with inverse propensity score weighting used to account for potential selection bias.ResultsThe study included 42 326 adults who switched to an HDHP (mean [SD] age, 52 [10] years; 19 752 [46.7%] female) and 202 729 adults who did not switch (mean [SD] age, 53 [10] years; 89 828 [44.3%] female). Those who switched to an HDHP had greater odds of experiencing all diabetes complications (odds ratio [OR], 1.11; 95% CI, 1.06-1.16 for myocardial infarction; OR, 1.15; 95% CI, 1.09-1.21 for stroke; OR, 1.35; 95% CI, 1.30-1.41 for hospitalization for heart failure; OR, 2.53; 95% CI, 2.38-2.70 for end-stage kidney disease; OR, 2.23; 95% CI, 2.17-2.29 for lower-extremity complication; OR, 1.17; 95% CI, 1.13-1.21 for proliferative retinopathy; OR, 2.35; 95% CI, 2.18-2.54 for blindness; and OR, 2.28; 95% CI, 2.15-2.41 for retinopathy treatment).Conclusions and RelevanceThis study found that an employer-driven switch to an HDHP was associated with increased odds of experiencing all diabetes complications. These findings reinforce the potential harm associated with HDHPs for people with diabetes and the importance of affordable and accessible chronic disease management, which is hindered by high out-of-pocket costs incurred by HDHPs.